Skip to content
naulon

No retraction, correction or concern found when last checked on Oct 23, 2026.

Cyclic GMP-AMP synthase promotes the inflammatory and autophagy responses in Huntington disease

Manish Sharma, Sumitha Rajendrarao, Neelam Shahani and 2 more

Proceedings of the National Academy of Sciences · 2020 · CC BY

doi:10.1073/pnas.2002144117

Abstract

Significance Huntington disease (HD) is a genetic disorder caused by glutamine-expansion in the huntingtin (mHTT) protein, which affects motor, psychiatric, and cognitive function, but the mechanisms remain unclear. mHTT is known to induce DNA damage and affect autophagy, both associated with inflammatory responses, but what mediates all these were unknown. Here we report that cGAS, a DNA damage sensor, is highly upregulated in the striatum of a mouse model and HD human patient’s tissue. We found ribosomes, which make proteins, are robustly accumulated on the cGAS mRNA in HD cells. cGAS depletion decreases—and cGAS expression increases—both inflammatory and autophagy responses in HD striatal cells. Thus, cGAS is a therapeutic target for HD. Blocking cGAS will prevent/slow down HD symptoms.

Full text

From PubMed Central, U.S. National Library of Medicine, as current on Oct 23, 2026. Paragraph numbers are ours, so an answer can point at one.

Huntington disease (HD) is a fatal neurodegenerative disorder that is caused by CAG expansion mutation of the Huntingtin gene (HTT), which codes for polyglutamine. The mutant gene, mHTT, is ubiquitously expressed, but it causes prominent damage to the striatum and cortex and subsequently leads to widespread peripheral defects as the disease progresses. Inflammatory responses have been implicated in the pathogenesis of HD, and compounds with anti-inflammatory properties have been shown to improve survival in HD transgenic mice. The number of microglia, a cellular indicator of inflammation, has been shown to be increased in the striatum of HD animal models, cell culture models, and HD patients. Additionally, the levels of reactive monocytes, inflammatory cytokines, chemokines, and the n-kynurenine/tryptophan ratio, which is an indicator of persistent inflammation, are all increased in premanifest HD patients, and are correlated with HD progression. Studies in mice indicate that glial cells and galectin molecules contribute to enhanced inflammatory responses in HD. Furthermore, RNA-sequencing (RNA-seq) analysis of tissue obtained from human HD patients and HD monkeys revealed extensive transcriptional dysregulation associated with the activation of pro-inflammatory pathways. Inflammation is also closely linked to autophagy, a catabolic process that is dysregulated in HD. These findings indicate that inflammation is a prominent cellular response in HD patients and across various HD models, although the mechanisms are not entirely clear.

cGMP-AMP synthase (cGAS, also known as Mb21d1) is an enzyme that produces cyclic guanosine monophosphate–adenosine monophosphate (cGMP-AMP or cGAMP), a second messenger that is activated upon binding of cGAS to DNA or RNA:DNA hybrids in the cytoplasm. cGAS can induce signaling that is known to promote the up-regulation of inflammatory genes and play a critical role in age-related macular degeneration and cellular senescence. cGAS-induced cGAMP binds to the endoplasmic reticulum (ER)-associated transmembrane protein STING (which is also known as TMEM173). STING recruits TANK-binding kinase 1 (TBK1), which phosphorylates transcription factors, such as IFN regulatory factor 3 (IRF3) and IFN regulatory factor 7 (IRF7), and other substrates, such as IκB kinase α (IKKα), cRel, and p62 (sequestosome). cGAS also plays a major role in the regulation of autophagy; this indicates that there is a close molecular and signaling link between inflammatory response and autophagy. The role of cGAS in cancer, diabetes, and immune disorders is well established, but its role in neurodegenerative disease remains less clear. Up-regulation of cGAMP/STING signaling, however, is linked to dopaminergic and cerebellar neuron degeneration in parkin-deficient and ataxia telangiectasia mice model, respectively. But the role of cGAS in HD remains unknown. Using ribosome profiling, biochemical, and molecular biology tools, we investigate the role of cGAS in HD.

High Ribosome Occupancy in Exon 1 of the cGAS mRNA in HD Cells.

Our study applies high-resolution ribosome sequencing (Ribo-seq) technology for the analysis of genetically precise knockin HD cell models: Immortalized STHdhQ7/Q7 (control), STHdhQ7/Q111 (HD-het), and STHdhQ111/Q111 (HD-homo) striatal neuronal cells derived from WT, HdhQ7/Q111, and HdhQ111/Q111 mouse embryos, respectively. In our previous study, we successfully generated high-quality reads and identified new roles for HTT as a physiological suppressor of translation via regulation of ribosome movement. The global ribosome profiling data of the present study revealed that cGAS, which has five exons, showed high ribosome occupancy (based on the ribosome-protected fragment [RPF]/mRNA ratio). The RPF counts in exon 1 of HD-het and HD-homo cells were higher than the counts in control cells (Fig. 1A, arrows). The ribosomes accumulated at the 5ʹ end of exon 1 in the region (TAC CTT CTA GGC GCA TCT TCC TGC TGC) that codes for MEDPRRRTT (Fig. 1 B, Inset, arrows); this indicates that the cGAS mRNA is translationally regulated in HD. With the help of a pause prediction software, we found an additional single codon pause at 171 (CCG) and 172 (CGT) in the HD cells (Fig. 1C, arrows). The gene, absence of melanoma 2 (Aim2), another cytosolic DNA sensor, was also up-regulated in HD cells, but to a much smaller extent than observed for cGAS (the RPF/mRNA for cGAS was 14, whereas it was 2.2 for Aim2 in HD-homo cells) (Fig. 1D). Similarly, hnRNP-A2b1, a newly identified sensor for viral double-stranded DNA—but not for endogenous DNA—in the nucleus, was found to be expressed at a similar level in the control and HD cells (Fig. 1E). Other known DNA sensors, such as Toll-like receptor 9, is mostly restricted to blood and immune cells but not expressed in striatal cells. We also examined whether the ribosome profile of two major cGAS downstream targets, namely Sting and Tbk1, is altered in HD cells. However, with the exception of a slight reduction in the RPF/mRNA ratio of Sting in HD-het cells, we found no major difference in the ribosome occupancy of Sting or Tbk1 between the control and HD cells (Fig. 1 F and G). Interestingly, Sting showed an expected pause at exon 3 (Fig. 1F, arrow), which might be necessary in cotranslational translocation for proper insertion into the ER. Together, the data indicate that the cGAS mRNA is selectively up-regulated in HD cells and shows high ribosome occupancy at exon 1, which may imply potential dysregulation of translation.

Up-Regulation of the cGAS Pathway in HD.

The high-ribosome occupancy of the cGAS mRNA indicates that ribosomes are potentially stalled on exon 1 (Fig. 1 A–C); this may result in an increase or decrease in protein production. Therefore, our next step was to investigate the protein levels of cGAS in HD cells. Western blot analysis showed that the cGAS protein is robustly up-regulated in HD-het and HD-homo striatal cells, but it is barely found in control striatal cells (Fig. 2A). Furthermore, the expression of cGAS in HD-homo cells was 60-fold higher than that in HD-het cells (Fig. 2A). cGAS up-regulation was also observed in a Q175HD-het (neo-) striatum (Fig. 2B) and in the striatum from human postmortem HD patients (Fig. 2C). The data indicate that the cGAS protein is up-regulated in HD; therefore, we investigated its activity.

Following activation of cGAS, cGAMP stimulates STING at the ER, which then promotes translocation of TBK1 to the endosomal and lysosomal compartment and leads to activation of the inflammatory response. STING is then is phosphorylated at Ser-365 (pSTING Ser365) by Ulk1, and it then facilitates the phosphorylation of TBK1 at Ser-172 (pTBK1 Ser172). Thus, pSTING (Ser365) and pTBK1 (Ser172) were used as downstream markers for the assessment of activation of cGAS signaling in HD. We observed that the phosphorylation level of STING (Ser365) was high in the HD-homo cells, but pSTING was not detected in control or HD-het cells (Fig. 2 D and E). Furthermore, phosphorylation of TBK1 (Ser172) was higher in both types of HD striatal cells than in the control cells (Fig. 2 D and E). We also observed an increase in the pTBK1 (Ser172) levels in Q175HD-het mice, as compared to the WT mice (Fig. 2 F and G), and in the striatum from HD patients as compared to the striatum from healthy controls (Fig. 2 H and I). These findings indicate that the expression and activity of cGAS are up-regulated in HD.

Up-Regulation of cGAS-Dependent Inflammatory Genes in HD.

Next, we investigated whether the levels of certain known cGAS-regulated inflammatory response genes are affected in HD, with the help of our ribosome profiling data. We examined the ribosome profiles of the mRNAs of cGAS-regulated inflammatory transcription factors (Irf3, Irf7) and inflammatory chemokines (Ccl5 and Cxcl10) in the HD and control cells (Fig. 3 A–D). We found no major differences in the RPF/mRNA ratio of Irf3 between HD-homo, HD-het, and control cells, but the RPF/mRNA ratio of Irf7 was slightly lower in HD-homo cells than in the control cells (1.5 vs. 2.2). This finding indicates that the ribosome occupancy of Irf7 is slightly decreased, but its mRNA levels are enhanced in HD-homo cells. Thus, there is no major difference in the RPF/mRNA ratio of the two known cGAS-regulated inflammatory transcription factors Irf3 and Irf7 between control and HD cells (Fig. 3 A and B). In contrast, we found that the RPF/mRNA ratios of Ccl5 and Cxcl10 are markedly higher in the HD cells: For Ccl5, the RPF/mRNA ratio was 3.5 in the HD-homo cells, while there were none or few reads in the HD-het and control cells. For Cxcl10, the RPF/mRNA ratio was 5.3 and 10.0 for the HD-homo and HD-het cells, respectively, and it was 3.2 in the control cells. Thus, enhanced mRNA expression and high ribosome occupancy were observed in the mRNA of the inflammatory chemokines, Ccl5 and Cxcl10, in HD cells. Interestingly, high ribosome occupancy was found on exon 3 of Ccl5 and Cxcl10; this is indicative of translational control of these mRNAs (Fig. 3 C and D, arrows).

Using qPCR analysis, we confirmed that the Ccl5 and Cxcl10 mRNAs are up-regulated in HD-het and HD-homo striatal cells (Fig. 3E) and in the Q175HD-het and Q175HD-homo mouse striatum (Fig. 3F), as well as striatum of grade 3 human HD patients (Fig. 3G). Although qPCR analysis showed that the Ccl5 and Cxcl10 mRNAs are not robustly altered in HD-het striatal cells (Fig. 3 E and F), we cannot exclude the possibility that the Ccl5 or Cxcl10 protein levels are increased in HD-het striatal cells, compared to the controls, because they show enhanced ribosome occupancy (Fig. 3 C and D). Collectively, these data indicate mRNA up-regulation of cGAS-dependent inflammatory response genes and altered ribosome occupancy of their mRNA in HD.

Effect of Depletion of cGAS on pSTING and pTBK1 Levels and Inflammatory Response in HD Cells.

To further establish a causal role for cGAS in the inflammatory response in HD, we explored whether depletion of cGAS could revert the inflammatory response. To this end, we transfected CRISPR/Cas9 gRNA directed against cGAS (cGAS depletion or cGASΔ) in the control, HD-het, and HD-homo striatal cells. We used nonspecific CRISPR/Cas9 gRNA (control gRNA) for the control groups. The cGASΔ HD-homo cells resulted in more than 80% depletion of cGAS (Fig. 3 H and I), as well as almost complete elimination of pSTING (Ser365) (Fig. 3 H and I) and significant reduction of pTBK1 (Ser172), which was also decreased in cGASΔ-HD-het cells (Fig. 3 H and I). Notably, pSTING (Ser365) was observed at negligible levels in the control and HD-het cells, presumably due to low cGAS levels (Fig. 3 H and J). Together, these findings indicate that cGAS depletion reduces the activation of its downstream targets, pSTING and pTBK1, in HD cells.

Next, we investigated whether cGAS depletion also interferes with the up-regulation of the inflammatory response in HD. For this, we performed qPCR analysis of Ccl5 and Cxcl10 in cGASΔ-HD-homo and control-HD-homo cells. cGAS depletion dramatically attenuated Ccl5 (Fig. 3I) and Cxcl10 (Fig. 3J) expression in the cGASΔ-HD-homo cells compared to the control-HD-homo cells. Taken together, these findings indicate that cGAS up-regulation is causally linked to the activation of its downstream signals as well as the inflammatory response.

Differences in LC3A and LC3B Levels and Ribosome Occupancy in HD Cells.

Previous studies indicate that autophagy is dysregulated in HD, and it is known that HTT plays several roles in regulating the dynamics of autophagy. During autophagy in mice, Atg proteases are cleaved at the glycine site (G) of pro-LC3A at ETFGF(stop) and pro-LC3B at ETFGTAMAV(stop) to generate LC3A-I and LC3B-I, respectively. LC3A-I and LC3B-I are further lipidated by the Atg enzyme to produce LC3A-II and LC3B-II, which bind to autophagosomes and initiate autophagy.

First, we used Western blot analysis to examine the status of LC3A and LC3B conversion in HD and control striatal cells, with the help of antibodies that detects both the I and II forms of LC3A and LC3B. In general, we observed higher basal LC3B-II levels than LC3A-II levels in all of the groups of striatal cells (Fig. 4A, arrows). However, both the LC3A-II and LC3B-II levels were higher in the HD cells than in the control cells (Fig. 4 A and B). This finding indicates that the steady-state basal autophagy levels are higher in HD cells than in control cells, as reported in previous studies.

Next, we explored why the basal LC3B-II conversion was higher than the basal LC3A-II conversion in HD cells (Fig. 4A, arrows). We speculated whether this difference was attributable to differences in the proforms of LC3A and LC3B in HD cells. As there are no antibodies available for the detection of the mouse or human proforms of LC3A and LC3B, we used the RPF/mRNA data (an indicator of ribosome occupancy) for LC3A and LC3B in the HD and control striatal cells as an indirect measurement of the levels of the uncleaved proforms of LC3A and LC3B. As shown in Fig. 4C, the LC3A mRNA, which has four exons, showed high ribosome occupancy in the 5ʹUTR (Fig. 4C, arrowheads), and in exon 3 and exon 4 (Fig. 4C, thin arrows) (compared to exons 1 and 2). The ribosome occupancy was slightly higher in the HD-homo cells (Fig. 4C, closed arrow) than in the HD-het and control cells. Moreover, the ribosomes appear stalled on exon 4 (Fig. 4 C, C1 Inset, arrowheads) just before the Atg cleavage site (ETFGF) and the stop codon (Fig. 4 C, C1 Inset), both in the HD and control cells. Next, the RPF/mRNA profile of LC3B exhibited four exons. High ribosome occupancy was observed on exon 4 (compared to exons 1, 2, and 3) in both the HD and control cells (Fig. 4D, arrowheads). Interestingly, in contrast to LC3A, the 5ʹUTR of LC3B did not show ribosome occupancy (Fig. 4D). Furthermore, in contrast to LC3A, the ribosomes appear stalled on exon 4 after the cleavage site of the protease Atg (Fig. 4 D, D1 Inset, arrowheads), and appeared to read through the stop codon and further into the 3ʹUTR (Fig. 4 D, D1 Inset, arrow).

Taken together, the RPF/mRNA data of LC3A and LC3B indicate that they are translationally regulated by the regulation of the ribosome occupancy, which might explain the higher basal levels of LC3B-II than LC3A-II in HD cells.

Role of cGAS in Mediating Autophagy Flux in HD Cells.

Previous studies indicate that the cGAS/STING pathway also regulates autophagy, which is a major catabolic process affected in HD. We, therefore, investigated the role of cGAS in the regulation of autophagy in HD cells. To this end, we examined basal autophagy in cGASΔ-HD-het, cGASΔ-HD-homo, and cGASΔ-control cells. The cGASΔ-HD-homo cells showed a robust reduction in LC3A-II (Fig. 4 E and F) and LC3B-II (Fig. 4 E and G), and the cGASΔ-HD-het cells showed a slight decrease in LC3A-II (Fig. 4 E and F) and LC3B-II (Fig. 4 E and G). This result indicates that cGAS up-regulation controls the autophagy response in HD cells.

Next, we investigated whether cGAS modulates autophagy flux in HD, as previous studies suggest that HD cells show enhanced autophagy flux as well as cargo-loading defects. We treated cGASΔ-HD-homo cells and control cells with chloroquine (CQ), which is a known inhibitor of autophagy flux. As shown in Fig. 4 H and I, we observed an ∼2.5-fold increase in LC3B-II conversion in HD-homo cells compared to control cells, and this difference was further enhanced in the presence of CQ. This finding indicates that basal autophagy flux is increased in HD. Finally, cGAS depletion (cGASΔ) in both vehicle- and CQ-treated HD-homo cells resulted in a decrease in LC3B-II formation compared to the corresponding control cells (Fig. 4 H and I). Together these results indicate that cGAS promotes autophagy flux in HD by enhancing LC3B-II formation (i.e., the formation of autophagosomes).

Effect of Reconstitution of cGAS on the Autophagy and Inflammatory Response in cGAS-Depleted HD Cells.

Next, we introduced exogenous GFP-tagged cGAS (GFP-cGAS) into cGASΔ-HD-homo cells and cGASΔ-control cells to confirm the role of cGAS in autophagy and inflammatory responses in HD. After the reconstitution of cGAS (cGASRe) in the cGASΔ-HD-homo cells, we observed robust induction of pSTING (Ser365) (Fig. 5 A and B) and pTBK1 (Ser172) (Fig. 5 A and C). In addition, cGASRe induced robust up-regulation of autophagy, as indicated by the LC3B-II conversion, in the cGASΔ-HD-homo cells (Fig. 5 A and D). cGASRe in the cGASΔ-HD-homo cells also resulted in an increase in the mRNA levels of the inflammatory response genes Ccl5 and Cxcl10, compared to the control cells (Fig. 5E). Notably, cGASRe in the cGASΔ-control cells also induced cGAS activity, and the autophagy and inflammatory responses, albeit at a lower level compared to HD-homo cells (Fig. 5). This finding indicates that mHTT is required for enhanced cGAS activity.

Together, these results indicate that cGAS reconstitution restores cGAS activity, and autophagy and inflammatory responses in cGAS-depleted HD cells. Thus, cGAS may play a critical role in the pathogenesis of HD.

cGAS Enrichment in Lysosomal and Mitochondrial Fractions and Coimmunoprecipitation with mHTT.

Previous studies have reported that cGAS is localized to the nucleus, plasma membrane, or intercellular organelles. We investigated the localization of cGAS in HD striatal cells by using a biochemical method (Fig. 6A). We found that cGAS was enriched in the cytoplasm, and a considerable amount was also detected in the nuclear fractions (Fig. 6A). To further investigate the intracellular localization of cGAS in the cytoplasm, we performed density-based gradient centrifugation and subcellular separation of organelles (Fig. 6B). We found that the cGAS-containing fractions sedimented at lighter density fractions that were enriched in autophagic/lysosomal markers and LC3B-II/LAMP1, as well as, to some extent in higher density fractions that were enriched in mitochondrial marker, SDHA (Fig. 6B). Thus, cGAS is enriched in the cytoplasm, lysosomal, and mitochondrial fractions in HD-homo striatal cells.

As mHTT interacts with multiple proteins, we examined whether mHTT also interacts with cGAS. Immunoprecipitation assay showed that cGAS does coimmunoprecipitate with mHTT. FMRP, a protein that is known to interact with mHTT, was also detected in the coimmunoprecipitated mHTT (Fig. 6C). This finding indicates that mHTT interacts with cGAS and may regulate its activity.

Enhanced Cytoplasmic Micronuclei in HD.

Finally, we considered the question of how cGAS is up-regulated. A previous study showed that cGAS can be up-regulated in the presence of cytoplasmic micronuclei, which are discrete DNA fragments that are independent of the main nucleus and may be indicative of DNA damage. Since we found rapid up-regulation of cGAS levels and activity in HD cells, we explored the possibility of micronuclei being present in HD cells. Indeed, we found numerous micronuclei in the HD-homo cells (43% of the cells), HD-het cells (30% of the cells) compared to the control cells (5% of the cells) (Fig. 6 D and E and SI Appendix, Fig. S1). Similarly, human HD striatal neurons, derived from human embryonic stem cells (hESCs), also showed numerous cytoplasmic micronuclei compared to neurons derived from unaffected hESCs (Fig. 6 F and G). We identified these neurons as medium spiny neurons (MSNs) as they were positive for DARPP-32, which is a marker of MSN (SI Appendix, Fig. S2). Together, these data indicate that HD cells harbor numerous micronuclei, which might contribute to the up-regulation of cGAS and its activity in HD.

Discussion

The data presented here demonstrate that cGAS is up-regulated in HD and is causally linked to the promotion of inflammatory and autophagy responses that might contribute to HD pathology (Fig. 6H). Our working model predict that the DNA damage/repair observed in HD may be a starting point for cGAS up-regulation (Fig. 6H). However, the mechanisms of DNA damage and repair or the formation of micronuclei, as discovered in this report and in an earlier report in HD, and how they trigger cGAS induction remain less clear.

Intriguingly, our Ribo-Seq and biochemical data showed that the ribosome occupancy of cGAS mRNA and its protein levels and activity are more enhanced in homozygous HD cells (HD-homo) than in heterozygous HD (HD-het) cells (Figs. 1 and 2). Thus, cGAS induction may be dependent on the copy number of mHTT. However, the mechanisms that contribute to the high ribosome occupancy in exon 1 of cGAS are unclear. Recently, we demonstrated that mHTT promotes stalling of ribosomes and inhibits global protein synthesis, and at the same time, the translation of select mRNA, such as Fmr1 mRNA, is increased in HD. Therefore, it is possible that mHTT directly regulates the translation of cGAS mRNA via the modulation of ribosome occupancy on exon 1. Alternatively, cGAS mRNA may be transcriptionally induced in response to DNA damage and repair. In fact, this may enhance exon 1 ribosome occupancy and cGAS production. However, it is not clear whether high ribosome occupancy on exon 1 of cGAS is restricted to HD cells or whether it is a ubiquitous “ribosome signature” of cGAS mRNA in all cell types.

With regard to the mechanism by which cGAS promotes inflammatory response in HD, it is known that the active cGAS-STING pathway activates TBK1, which phosphorylates the transcription factors IRF3/IRF7, and these factors, in turn, regulate the inflammatory cytokines Ccl5 and Cxcl10. The active TBK1 can also promote Ccl5 and Cxcl10 expression via Tlr signaling; thus, the inflammatory responses in HD may involve cGAS-dependent and cGAS-independent pathways. Previous studies have reported that Ccl5 and Cxcl10 are up-regulated in various HD models. Interestingly, mHTT has been shown to inhibit the secretion of the Ccl5 protein, as immunocytochemical analysis showed stronger intracellular Ccl5 protein accumulation in HD astrocytes than in WT astrocytes. Our data indicate high ribosome occupancy on exon 3 of Ccl5 in HD cells (Fig. 3C). The high ribosome occupancy of Ccl5 could contribute to its defective secretion in HD, but this needs to be explored in a future study. Importantly, mHTT in astrocytes has been shown to influence the pathogenesis of HD, and physiological cGAS expression has been found to be higher in astrocytes than in neurons. Thus, cGAS might orchestrate the inflammatory response in HD via the canonical STING/TBK1 signaling pathway in nonneuronal cells.

Our study findings demonstrate the critical role of cGAS in the regulation of autophagy in HD cells. Previously, it was demonstrated that cGAS induced the activation and translocation of STING to the ER–Golgi intermediate compartment, which serves as the source for LC3-II formation. Interestingly, HTT can act as a scaffold for autophagy initiation by bringing together other autophagy regulators, such as p62 and ULK1 kinase, and promoting the formation of autophagosomes. Autophagy flux has been shown to be increased in HD, but HD cells also demonstrate defects in cargo delivery and loading into autophagosomes. Thus, the mechanisms of autophagy flux or its defects in HD are not fully understood. We found high basal levels of LC3A-II and LC3B-II in HD striatal cells, compared to control cells, and demonstrated that HD cells show enhanced autophagy flux (Fig. 4). As cGAS is a known inducer of autophagy flux via enhancement of LC3-II formation, we propose that cGAS may serve as a major regulator of autophagy flux in HD. However, it is not clear whether the cGAS-STING pathway alone is responsible for the autophagy flux in HD, or whether cGAS and mHTT affect different domains of the autophagy flux.

Although TBK1 has been shown to play a major role in cGAS-mediated inflammatory response, it has been demonstrated that cGAS-STING–mediated autophagy flux is TBK1-independent. However, TBK1 is involved in promoting autophagosome maturation. In this report, we demonstrated that TBK1 is highly up-regulated in HD cells, and its activity is dependent on cGAS. However, the HD-het cells displayed TBK1 activation that was high and comparable to that of HD-homo cells, even though they had very low cGAS levels (Fig. 2 A and D). Based on these findings, we propose that aberrant autophagy in HD can occur in a cGAS-dependent or TBK1-dependent fashion, and can affect both autophagosome formation and maturation. Moreover, mHTT, like TBK1, also regulates p62, NF-kB signaling, and mechanistic target of rapamycin complex 1 (mTORC1) signaling. Thus, mHTT and TBK1 may play a synergistic role in HD progression via more than one pathway.

Based on our Ribo-seq data, which is derived from isolating actively translating 80S ribosomes, for LC3A and LC3B mRNA, we predict the following: the ribosome occupancy on the 5ʹUTR of LC3A (Fig. 4C) may indicate that LC3A is translated through the 5ʹUTR or that it is involved in 5ʹUTR-dependent translational regulation. Furthermore, the ribosomes that accumulate after the cleavage site of the conserved protease Atg on exon 4 of LC3B mRNA and stop-codon read-through (Fig. 4D) may serve as a site for pro-LC3B cleavage by Atg to generate LC3B-I. Such a cotranslational mechanism may occur, for example, by the recruitment of protease Atg to the stop-codon read-through stalled ribosomes to generate the LC3B-I needed for lipidation and autophagy initiation. Analogous cotranslational proteolytic events are described for N-terminal methionine excision events that unmask glycine for lipidation, which is required for cell-signaling mechanisms. Therefore, we predict that LC3A and LC3B may be differentially regulated via cotranslational proteolytic events to initiate autophagy, which might additionally contribute to the cGAS-mediated autophagy in HD.

The striatum is the most vulnerable region in HD. However, the mechanisms that promotes striatal damage remain unclear, as do the mechanisms via which cGAS activation in HD regulates striatal vulnerability. We speculate that in the striatum, Rhes, a GTPase/SUMOE3-like protein, which increases mHTT solubility and promotes cell-to-cell transport of mHTT via tunneling-nanotube–like membrane protrusions, might participate in cGAS activity and propagate inflammatory and autophagy responses via intercellular signaling.

Our mechanistic model, which is based on data integrated from ribosome profiling, and molecular and biochemical approaches, provides deep insight into the causal role of cGAS signaling in fostering inflammatory and autophagic responses in the HD cell model. Thus, our study illustrates the translational potential of cGAS inhibition in alleviating HD symptoms and progression.

Cell Culture, Antibodies, Plasmids, and Human Tissue.

Mouse STHdhQ7/Q7 (control), STHdhQ7/Q111 (HD-het), and STHdhQ111/Q111 (HD-homo) striatal neuronal cells were obtained from the Coriell Institute and cultured as described in our previous works. For autophagy flux measurements, 50 μM CQ (dissolved in water) was added to cells for 4 h. Details about antibodies plasmids and human tissue used in the study can be found in SI Appendix. cDNA preparation, real-time PCR, nuclear/cytoplasmic and subcellular fractionation, Western blotting, and imaging details can be found in SI Appendix.

hESC-Derived Neuron Culture.

Unaffected (Genea-019) and HD-affected (HTT-48Q, Genea-020) hESC lines were obtained from the Cure Huntington Disease Initiative. The lines were grown and expanded in feeder-free conditions on vitronectin using Essential 8 plus medium (Thermo Fisher Scientific) at 37 °C and 5% CO2. Medium was replaced daily. hESCs were differentiated into striatal neurons using a previously described protocol (SI Appendix).

Ribosome Profiling.

RNase foot printing, generation of cDNA libraries from ribosome protected mRNAs, generation of cDNA libraries and sequencing, generation of mRNA-seq libraries, Ribo-seq, RNA-seq quality control, and mapping the reads to the University of California, Santa Cruz (UCSC) browser and ribosome pause analysis, were carried out as described in our previous work. A full UCSC Genome Browser link for the global ribosome footprints pooling all three replicates for control, HD-het and HD-homo cells can be found at https://genome.ucsc.edu/cgi-bin/hgTracks?hubUrl=Https://de.cyverse.org/anon-files/iplant/home/rmi2lab/Hub_Collaborations/Srini/hub.txt&genome=mm10.

Mice.

C57BL/6J (WT) and the zQ175 neo-deleted knockin mouse (B6J.129S1-Htttm1.1Mfc/190ChdiJ, stock no. 029928) obtained from Jackson Laboratories and maintained in our animal facility according to Institutional Animal Care and Use Committee at The Scripps Research Institute. Three- to 4-mo-old mice were used for the experiment.

Generation of cGAS-Depleted Striatal Cells.

cGAS-depleted striatal cells (cGASΔ) were generated using cGAS CRISPR/Cas9 plasmids from Santa Cruz Biotechnologies, as described previously. (SI Appendix).

Statistical Analysis.

Unless otherwise noted, all experiments were carried out in duplicates and repeated at least three times. The statistical comparison was carried out between groups using one-way ANOVA followed by Tukey’s multiple comparison test or Student’s t test, and significance values were set at P < 0.05, using GraphPad Prism 7.

Data Availability.

Sequencing data have been submitted to the Gene Expression Omnibus (GEO) data repository, under accession no. GSE146674.

References 106

  1. 1.
  2. 2.

    F. Agus, D. Crespo, R. H. Myers, A. Labadorf, The caudate nucleus undergoes dramatic and unique transcriptional changes in human prodromal Huntington’s disease brain. BMC Med. Genomics 12, 137 (2019 ).

    Not in our library10.1186/s12920-019-0581-9

  3. 3.

    A. Crotti, C. K. Glass, The choreography of neuroinflammation in Huntington’s disease. Trends Immunol. 36, 364–373 (2015 ).

    Not in our library10.1016/j.it.2015.04.007

  4. 4.

    K. Messmer, G. P. Reynolds, Increased peripheral benzodiazepine binding sites in the brain of patients with Huntington’s disease. Neurosci. Lett. 241, 53–56 (1998 ).

    Not in our library10.1016/s0304-3940(97)00967-1

  5. 5.

    M. R. von Essen., Early intrathecal T helper 17.1 cell activity in Huntington disease. Ann. Neurol. 87, 246–255 (2020 ).

    Not in our library10.1002/ana.25647

  6. 6.

    S. A. Liddelow., Neurotoxic reactive astrocytes are induced by activated microglia. Nature 541, 481–487 (2017 ).

    Not in our library10.1038/nature21029

  7. 7.

    C. Stack., Triterpenoids CDDO-ethyl amide and CDDO-trifluoroethyl amide improve the behavioral phenotype and brain pathology in a transgenic mouse model of Huntington’s disease. Free Radic. Biol. Med. 49, 147–158 (2010 ).

    Not in our library10.1016/j.freeradbiomed.2010.03.017

  8. 8.

    H. Kalonia, A. Kumar, Suppressing inflammatory cascade by cyclo-oxygenase inhibitors attenuates quinolinic acid induced Huntington’s disease-like alterations in rats. Life Sci. 88, 784–791 (2011 ).

    Not in our library10.1016/j.lfs.2011.02.020

  9. 9.

    N. Pavese., Microglial activation correlates with severity in Huntington disease: A clinical and PET study. Neurology 66, 1638–1643 (2006 ).

    Not in our library10.1212/01.wnl.0000222734.56412.17

  10. 10.

    E. Sapp., Early and progressive accumulation of reactive microglia in the Huntington disease brain. J. Neuropathol. Exp. Neurol. 60, 161–172 (2001 ).

    Not in our library10.1093/jnen/60.2.161

  11. 11.

    A. D. Kraft, L. S. Kaltenbach, D. C. Lo, G. J. Harry, Activated microglia proliferate at neurites of mutant huntingtin-expressing neurons. Neurobiol. Aging 33, 621.e17-633 (2012 ).

    Not in our library10.1016/j.neurobiolaging.2011.02.015

  12. 12.

    M. Björkqvist., A novel pathogenic pathway of immune activation detectable before clinical onset in Huntington’s disease. J. Exp. Med. 205, 1869–1877 (2008 ).

    Not in our library10.1084/jem.20080178

  13. 13.

    N. Stoy., Tryptophan metabolism and oxidative stress in patients with Huntington’s disease. J. Neurochem. 93, 611–623 (2005 ).

    Not in our library10.1111/j.1471-4159.2005.03070.x

  14. 14.

    F. Sánchez-López., Oxidative stress and inflammation biomarkers in the blood of patients with Huntington’s disease. Neurol. Res. 34, 721–724 (2012 ).

    Not in our library10.1179/1743132812y.0000000073

  15. 15.

    C. Lois., Neuroinflammation in Huntington’s disease: New insights with 11C-PBR28 PET/MRI. ACS Chem. Neurosci. 9, 2563–2571 (2018 ).

    Not in our library10.1021/acschemneuro.8b00072

  16. 16.

    H. Y. Hsiao, Y. C. Chen, H. M. Chen, P. H. Tu, Y. Chern, A critical role of astrocyte-mediated nuclear factor-κB-dependent inflammation in Huntington’s disease. Hum. Mol. Genet. 22, 1826–1842 (2013 ).

    Not in our library10.1093/hmg/ddt036

  17. 17.
  18. 18.

    J. R. Miller., RNA-seq of Huntington’s disease patient myeloid cells reveals innate transcriptional dysregulation associated with proinflammatory pathway activation. Hum. Mol. Genet. 25, 2893–2904 (2016 ).

    Not in our library10.1093/hmg/ddw142

  19. 19.

    J. Raper., Increased irritability, anxiety, and immune reactivity in transgenic Huntington’s disease monkeys. Brain Behav. Immun. 58, 181–190 (2016 ).

    Not in our library10.1016/j.bbi.2016.07.004

  20. 20.

    Y. Matsuzawa-Ishimoto, S. Hwang, K. Cadwell, Autophagy and inflammation. Annu. Rev. Immunol. 36, 73–101 (2018 ).

    Not in our library10.1146/annurev-immunol-042617-053253

  21. 21.

    D. D. Martin, S. Ladha, D. E. Ehrnhoefer, M. R. Hayden, Autophagy in Huntington disease and huntingtin in autophagy. Trends Neurosci. 38, 26–35 (2015 ).

    Not in our library10.1016/j.tins.2014.09.003

  22. 22.

    L. Sun, J. Wu, F. Du, X. Chen, Z. J. Chen, Cyclic GMP-AMP synthase is a cytosolic DNA sensor that activates the type I interferon pathway. Science 339, 786–791 (2013 ).

    Not in our library10.1126/science.1232458

  23. 23.

    A. K. Mankan., Cytosolic RNA:DNA hybrids activate the cGAS-STING axis. EMBO J. 33, 2937–2946 (2014 ).

    Not in our library10.15252/embj.201488726

  24. 24.

    H. Yang, H. Wang, J. Ren, Q. Chen, Z. J. Chen, cGAS is essential for cellular senescence. Proc. Natl. Acad. Sci. U.S.A. 114, E4612–E4620 (2017 ).

    Not in our library10.1073/pnas.1705499114

  25. 25.

    S. Glück., Innate immune sensing of cytosolic chromatin fragments through cGAS promotes senescence. Nat. Cell Biol. 19, 1061–1070 (2017 ).

    Not in our library10.1038/ncb3586

  26. 26.

    N. Kerur., cGAS drives noncanonical-inflammasome activation in age-related macular degeneration. Nat. Med. 24, 50–61 (2018 ).

    Not in our library10.1038/nm.4450

  27. 27.

    E. Helgason, Q. T. Phung, E. C. Dueber, Recent insights into the complexity of Tank-binding kinase 1 signaling networks: The emerging role of cellular localization in the activation and substrate specificity of TBK1. FEBS Lett. 587, 1230–1237 (2013 ).

    Not in our library10.1016/j.febslet.2013.01.059

  28. 28.

    J. Bai, F. Liu, The cGAS-cGAMP-STING pathway: A molecular link between immunity and metabolism. Diabetes 68, 1099–1108 (2019 ).

    Not in our library10.2337/dbi18-0052

  29. 29.
  30. 30.

    Z. Lei., cGAS-mediated autophagy protects the liver from ischemia-reperfusion injury independently of STING. Am. J. Physiol. Gastrointest. Liver Physiol. 314, G655–G667 (2018 ).

    Not in our library10.1152/ajpgi.00326.2017

  31. 31.

    Q. Liang., Autophagy side of MB21D1/cGAS DNA sensor. Autophagy 10, 1146–1147 (2014 ).

    Not in our library10.4161/auto.28769

  32. 32.

    H. S. Hwang, M. H. Lee, M. H. Choi, H. A. Kim, Induction of pro-inflammatory cytokines by 29-kDa FN-f via cGAS/STING pathway. BMB Rep. 52, 336–341 (2019 ).

    Not in our library10.5483/bmbrep.2019.52.5.072

  33. 33.

    L. D. Aarreberg., Interleukin-1beta induces mtDNA release to activate innate immune signaling via cGAS-STING. Mol. Cell 74, 801–815.e6 (2019 ).

    Not in our library10.1016/j.molcel.2019.02.038

  34. 34.

    V. Bader, K. F. Winklhofer, Mitochondria at the interface between neurodegeneration and neuroinflammation. Semin. Cell Dev. Biol. 99, 163–171 (2020 ).

    Not in our library10.1016/j.semcdb.2019.05.028

  35. 35.

    D. A. Sliter., Parkin and PINK1 mitigate STING-induced inflammation. Nature 561, 258–262 (2018 ).

    Not in our library10.1038/s41586-018-0448-9

  36. 36.

    H. Quek., A rat model of ataxia-telangiectasia: Evidence for a neurodegenerative phenotype. Hum. Mol. Genet. 26, 109–123 (2017 ).

    Not in our library10.1093/hmg/ddw371

  37. 37.

    F. Trettel., Dominant phenotypes produced by the HD mutation in STHdh(Q111) striatal cells. Hum. Mol. Genet. 9, 2799–2809 (2000 ).

    Not in our library10.1093/hmg/9.19.2799

  38. 38.

    M. Eshraghi., Global ribosome profiling reveals that mutant huntingtin stalls ribosomes and represses protein synthesis independent of fragile X mental retardation protein. bioRxiv:10.1101/629667 (7 May 2019).

    Not in our library

  39. 39.

    R. Kumari, A. M. Michel, P. V. Baranov, PausePred and Rfeet: Webtools for inferring ribosome pauses and visualizing footprint density from ribosome profiling data. RNA 24, 1297–1304 (2018 ).

    Not in our library10.1261/rna.065235.117

  40. 40.

    S. Emming, K. Schroder, Tiered DNA sensors for escalating responses. Science 365, 1375–1376 (2019 ).

    Not in our library10.1126/science.aay2701

  41. 41.

    A. Eaton-Bassiri., Toll-like receptor 9 can be expressed at the cell surface of distinct populations of tonsils and human peripheral blood mononuclear cells. Infect. Immun. 72, 7202–7211 (2004 ).

    Not in our library10.1128/iai.72.12.7202-7211.2004

  42. 42.

    K. J. Mackenzie., cGAS surveillance of micronuclei links genome instability to innate immunity. Nature 548, 461–465 (2017 ).

    Not in our library10.1038/nature23449

  43. 43.

    H. Ishikawa, G. N. Barber, STING is an endoplasmic reticulum adaptor that facilitates innate immune signalling. Nature 455, 674–678 (2008 ).

    Not in our library10.1038/nature07317

  44. 44.

    A. L. Southwell., An enhanced Q175 knock-in mouse model of Huntington disease with higher mutant huntingtin levels and accelerated disease phenotypes. Hum. Mol. Genet. 25, 3654–3675 (2016 ).

    Not in our library10.1093/hmg/ddw212

  45. 45.

    H. Konno, K. Konno, G. N. Barber, Cyclic dinucleotides trigger ULK1 (ATG1) phosphorylation of STING to prevent sustained innate immune signaling. Cell 155, 688–698 (2013 ).

    Not in our library10.1016/j.cell.2013.09.049

  46. 46.

    T. Li, Z. J. Chen, The cGAS-cGAMP-STING pathway connects DNA damage to inflammation, senescence, and cancer. J. Exp. Med. 215, 1287–1299 (2018 ).

    Not in our library10.1084/jem.20180139

  47. 47.

    Y. Tanaka, Z. J. Chen, STING specifies IRF3 phosphorylation by TBK1 in the cytosolic DNA signaling pathway. Sci. Signal. 5, ra20 (2012 ).

    Not in our library10.1126/scisignal.2002521

  48. 48.

    S. Liu., Phosphorylation of innate immune adaptor proteins MAVS, STING, and TRIF induces IRF3 activation. Science 347, aaa2630 (2015 ).

    Not in our library10.1126/science.aaa2630

  49. 49.

    N. J. Parekh., Type I interferon-dependent CCL4 is induced by a cGAS/STING pathway that bypasses viral inhibition and protects infected tissue, independent of viral burden. PLoS Pathog. 15, e1007778 (2019 ).

    Not in our library10.1371/journal.ppat.1007778

  50. 50.

    X. D. Li., Pivotal roles of cGAS-cGAMP signaling in antiviral defense and immune adjuvant effects. Science 341, 1390–1394 (2013 ).

    Not in our library10.1126/science.1244040

  51. 51.

    J. J. Suschak, S. Wang, K. A. Fitzgerald, S. Lu, A cGAS-independent STING/IRF7 pathway mediates the immunogenicity of DNA vaccines. J. Immunol. 196, 310–316 (2016 ).

    Not in our library10.4049/jimmunol.1501836

  52. 52.

    R. Corral., Comprehensive analyses of DNA repair pathways, smoking and bladder cancer risk in Los Angeles and Shanghai. Int. J. Cancer 135, 335–347 (2014 ).

    Not in our library10.1002/ijc.28693

  53. 53.

    I. Tanida, T. Ueno, E. Kominami, Human light chain 3/MAP1LC3B is cleaved at its carboxyl-terminal Met121 to expose Gly120 for lipidation and targeting to autophagosomal membranes. J. Biol. Chem. 279, 47704–47710 (2004 ).

    Not in our library10.1074/jbc.m407016200

  54. 54.

    C. E. Zois., “Autophagic flux” in normal mouse tissues: Focus on endogenous LC3A processing. Autophagy 7, 1371–1378 (2011 ).

    Not in our library10.4161/auto.7.11.16664

  55. 55.

    I. Dikic, Z. Elazar, Mechanism and medical implications of mammalian autophagy. Nat. Rev. Mol. Cell Biol. 19, 349–364 (2018 ).

    Not in our library10.1038/s41580-018-0003-4

  56. 56.

    K. Pircs., Huntingtin aggregation impairs autophagy, leading to argonaute-2 accumulation and global MicroRNA dysregulation. Cell Rep. 24, 1397–1406 (2018 ).

    Not in our library10.1016/j.celrep.2018.07.017

  57. 57.

    C. Erie, M. Sacino, L. Houle, M. L. Lu, J. Wei, Altered lysosomal positioning affects lysosomal functions in a cellular model of Huntington’s disease. Eur. J. Neurosci. 42, 1941–1951 (2015 ).

    Not in our library10.1111/ejn.12957

  58. 58.

    M. Martinez-Vicente., Cargo recognition failure is responsible for inefficient autophagy in Huntington’s disease. Nat. Neurosci. 13, 567–576 (2010 ).

    Not in our library10.1038/nn.2528

  59. 59.

    K. R. Croce, A. Yamamoto, A role for autophagy in Huntington’s disease. Neurobiol. Dis. 122, 16–22 (2019 ).

    Not in our library10.1016/j.nbd.2018.08.010

  60. 60.

    Y. N. Rui, Z. Xu, B. Patel, A. M. Cuervo, S. Zhang, HTT/Huntingtin in selective autophagy and Huntington disease: A foe or a friend within? Autophagy 11, 858–860 (2015 ).

    Not in our library10.1080/15548627.2015.1039219

  61. 61.

    M. Mauthe., Chloroquine inhibits autophagic flux by decreasing autophagosome-lysosome fusion. Autophagy 14, 1435–1455 (2018 ).

    Not in our library10.1080/15548627.2018.1474314

  62. 62.

    N. Mizushima, T. Yoshimori, B. Levine, Methods in mammalian autophagy research. Cell 140, 313–326 (2010 ).

    Not in our library10.1016/j.cell.2010.01.028

  63. 63.

    K. C. Barnett., Phosphoinositide interactions position cGAS at the plasma membrane to ensure efficient distinction between self- and viral DNA. Cell 176, 1432–1446.e11 (2019 ).

    Not in our library10.1016/j.cell.2019.01.049

  64. 64.
  65. 65.
  66. 66.

    A. Russo, F. Degrassi, Molecular cytogenetics of the micronucleus: Still surprising. Mutat Res Genet Toxicol Environ Mutagen 836, 36–40 (2018 ).

    Not in our library10.1016/j.mrgentox.2018.05.011

  67. 67.

    T. H. Massey, L. Jones, The central role of DNA damage and repair in CAG repeat diseases. Dis. Model. Mech. 11, dmm031930 (2018 ).

    Not in our library10.1242/dmm.031930

  68. 68.

    G. Askeland., Increased nuclear DNA damage precedes mitochondrial dysfunction in peripheral blood mononuclear cells from Huntington’s disease patients. Sci. Rep. 8, 9817 (2018 ).

    Not in our library10.1038/s41598-018-27985-y

  69. 69.

    E. Dragileva., Intergenerational and striatal CAG repeat instability in Huntington’s disease knock-in mice involve different DNA repair genes. Neurobiol. Dis. 33, 37–47 (2009 ).

    Not in our library10.1016/j.nbd.2008.09.014

  70. 70.

    T. Maiuri., DNA damage repair in Huntington’s disease and other neurodegenerative diseases. Neurotherapeutics 16, 948–956 (2019 ).

    Not in our library10.1007/s13311-019-00768-7

  71. 71.

    K. Sathasivam., Centrosome disorganization in fibroblast cultures derived from R6/2 Huntington’s disease (HD) transgenic mice and HD patients. Hum. Mol. Genet. 10, 2425–2435 (2001 ).

    Not in our library10.1093/hmg/10.21.2425

  72. 72.

    M. Farlik., Contribution of a TANK-binding kinase 1-interferon (IFN) regulatory factor 7 pathway to IFN-γ-induced gene expression. Mol. Cell Biol. 32, 1032–1043 (2012 ).

    Not in our library10.1128/mcb.06021-11

  73. 73.

    C. Zierhut., The cytoplasmic DNA sensor cGAS promotes mitotic cell death. Cell 178, 302–315.e23 (2019 ).

    Not in our library10.1016/j.cell.2019.05.035

  74. 74.

    X. Dong, S. Cong, Identification of differentially expressed genes and regulatory relationships in Huntington’s disease by bioinformatics analysis. Mol. Med. Rep. 17, 4317–4326 (2018 ).

    Not in our library10.3892/mmr.2018.8410

  75. 75.
  76. 76.

    S. Y. Chou., Expanded-polyglutamine huntingtin protein suppresses the secretion and production of a chemokine (CCL5/RANTES) by astrocytes. J. Neurosci. 28, 3277–3290 (2008 ).

    Not in our library10.1523/jneurosci.0116-08.2008

  77. 77.

    J. Bradford., Expression of mutant huntingtin in mouse brain astrocytes causes age-dependent neurological symptoms. Proc. Natl. Acad. Sci. U.S.A. 106, 22480–22485 (2009 ).

    Not in our library10.1073/pnas.0911503106

  78. 78.

    M. Faideau., In vivo expression of polyglutamine-expanded huntingtin by mouse striatal astrocytes impairs glutamate transport: A correlation with Huntington’s disease subjects. Hum. Mol. Genet. 19, 3053–3067 (2010 ).

    Not in our library10.1093/hmg/ddq212

  79. 79.
  80. 80.

    D. D. Martin., Identification of a post-translationally myristoylated autophagy-inducing domain released by caspase cleavage of huntingtin. Hum. Mol. Genet. 23, 3166–3179 (2014 ).

    Not in our library10.1093/hmg/ddu027

  81. 81.

    J. Ochaba., Potential function for the Huntingtin protein as a scaffold for selective autophagy. Proc. Natl. Acad. Sci. U.S.A. 111, 16889–16894 (2014 ).

    Not in our library10.1073/pnas.1420103111

  82. 82.

    Y. N. Rui., Huntingtin functions as a scaffold for selective macroautophagy. Nat. Cell Biol. 17, 262–275 (2015 ).

    Not in our library10.1038/ncb3101

  83. 83.

    M. Y. Heng, P. J. Detloff, H. L. Paulson, R. L. Albin, Early alterations of autophagy in Huntington disease-like mice. Autophagy 6, 1206–1208 (2010 ).

    Not in our library10.4161/auto.6.8.13617

  84. 84.

    E. Wong, A. M. Cuervo, Autophagy gone awry in neurodegenerative diseases. Nat. Neurosci. 13, 805–811 (2010 ).

    Not in our library10.1038/nn.2575

  85. 85.

    M. Pilli., TBK-1 promotes autophagy-mediated antimicrobial defense by controlling autophagosome maturation. Immunity 37, 223–234 (2012 ).

    Not in our library10.1016/j.immuni.2012.04.015

  86. 86.
  87. 87.

    M. Kurosawa., Depletion of p62 reduces nuclear inclusions and paradoxically ameliorates disease phenotypes in Huntington’s model mice. Hum. Mol. Genet. 24, 1092–1105 (2015 ).

    Not in our library10.1093/hmg/ddu522

  88. 88.

    M. Napolitano., NF-kB/NOS cross-talk induced by mitochondrial complex II inhibition: Implications for Huntington’s disease. Neurosci. Lett. 434, 241–246 (2008 ).

    Not in our library10.1016/j.neulet.2007.09.056

  89. 89.

    U. Träger., HTT-lowering reverses Huntington’s disease immune dysfunction caused by NFκB pathway dysregulation. Brain 137, 819–833 (2014 ).

    Not in our library10.1093/brain/awt355

  90. 90.

    E. Marcora, M. B. Kennedy, The Huntington’s disease mutation impairs Huntingtin’s role in the transport of NF-κB from the synapse to the nucleus. Hum. Mol. Genet. 19, 4373–4384 (2010 ).

    Not in our library10.1093/hmg/ddq358

  91. 91.

    Z. Yu, D. Zhou, G. Cheng, M. P. Mattson, Neuroprotective role for the p50 subunit of NF-kappaB in an experimental model of Huntington’s disease. J. Mol. Neurosci. 15, 31–44 (2000 ).

    Not in our library10.1385/jmn:15:1:31

  92. 92.

    W. M. Pryor., Huntingtin promotes mTORC1 signaling in the pathogenesis of Huntington’s disease. Sci. Signal. 7, ra103 (2014 ).

    Not in our library10.1126/scisignal.2005633

  93. 93.

    N. T. Ingolia, L. F. Lareau, J. S. Weissman, Ribosome profiling of mouse embryonic stem cells reveals the complexity and dynamics of mammalian proteomes. Cell 147, 789–802 (2011 ).

    Not in our library10.1016/j.cell.2011.10.002

  94. 94.

    N. T. Ingolia, Ribosome profiling: New views of translation, from single codons to genome scale. Nat. Rev. Genet. 15, 205–213 (2014 ).

    Not in our library10.1038/nrg3645

  95. 95.
  96. 96.

    K. Leppek, R. Das, M. Barna, Functional 5′ UTR mRNA structures in eukaryotic translation regulation and how to find them. Nat. Rev. Mol. Cell Biol. 19, 158–174 (2018 ).

    Not in our library10.1038/nrm.2017.103

  97. 97.

    M. B. Schaaf, T. G. Keulers, M. A. Vooijs, K. M. Rouschop, LC3/GABARAP family proteins: Autophagy-(un)related functions. FASEB J. 30, 3961–3978 (2016 ).

    Not in our library10.1096/fj.201600698r

  98. 98.

    F. Frottin., Cotranslational proteolysis dominates glutathione homeostasis to support proper growth and development. Plant Cell 21, 3296–3314 (2009 ).

    Not in our library10.1105/tpc.109.069757

  99. 99.

    M. Sharma, S. Subramaniam, Rhes travels from cell to cell and transports Huntington disease protein via TNT-like protrusion. J. Cell Biol. 218, 1972–1993 (2019 ).

    Not in our library10.1083/jcb.201807068

  100. 100.

    M. Sharma., Rhes, a striatal-enriched protein, promotes mitophagy via Nix. Proc. Natl. Acad. Sci. U.S.A. 116, 23760–23771 (2019 ).

    Not in our library10.1073/pnas.1912868116

  101. 101.

    S. Subramaniam, K. M. Sixt, R. Barrow, S. H. Snyder, Rhes, a striatal specific protein, mediates mutant-huntingtin cytotoxicity. Science 324, 1327–1330 (2009 ).

    Not in our library10.1126/science.1172871

  102. 102.

    R. G. Mealer, A. J. Murray, N. Shahani, S. Subramaniam, S. H. Snyder, Rhes, a striatal-selective protein implicated in Huntington disease, binds beclin-1 and activates autophagy. J. Biol. Chem. 289, 3547–3554 (2014 ).

    Not in our library10.1074/jbc.m113.536912

  103. 103.

    S. Swarnkar., Ectopic expression of the striatal-enriched GTPase Rhes elicits cerebellar degeneration and an ataxia phenotype in Huntington’s disease. Neurobiol. Dis. 82, 66–77 (2015 ).

    Not in our library10.1016/j.nbd.2015.05.011

  104. 104.

    S. Subramaniam, Rhes tunnels: A radical new way of communication in the brain’s striatum? BioEssays 42, e1900231 (2020 ).

    Not in our library10.1002/bies.201900231

  105. 105.

    N. Shahani., RasGRP1 promotes amphetamine-induced motor behavior through a Rhes interaction network (“Rhesactome”) in the striatum. Sci. Signal. 9, ra111 (2016 ).

    Not in our library10.1126/scisignal.aaf6670

  106. 106.

    M. Wu., A chemical recipe for generation of clinical-grade striatal neurons from hESCs. Stem Cell Reports 11, 635–650 (2018 ).

    Not in our library10.1016/j.stemcr.2018.08.005

Cited by papers we hold 7

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.